Olamkicept

Drug Profile

Olamkicept

Alternative Names: FE-301; FE-999301; TJ-301

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Conaris Research Institute
  • Developer Ferring Pharmaceuticals
  • Class Anti-inflammatories; Glycoproteins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory bowel diseases
  • No development reported Crohn's disease

Most Recent Events

  • 07 Sep 2017 No development reported - Phase-II for Crohn's disease (IV)
  • 08 Aug 2017 Leading Biopharm plans a phase II trial for Ulcerative colitis (NCT03235752)
  • 19 Dec 2016 Olamkicept licensed to IMAB in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top